T. Jacoby

Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.

K. Reynolds, S.T. Chen, N. Shah, 2022, JAMA dermatology.

Histopathologically‐confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: a retrospective cohort analysis

K. Reynolds, L. Thompson, S.T. Chen, 2021, The British journal of dermatology.

Neutrophilic Dermatosis and Management Strategies for the Inpatient Dermatologist

S.T. Chen, N. Shah, M. Asdourian, 2022, Current Dermatology Reports.

The role of bioidentical hormone replacement therapy in anti‐aging medicine: a review of the literature

A. Rosenthal, R. Moy, Rachel N. Israilevich, 2020, International journal of dermatology.

Dermatology evaluation for cutaneous immune related adverse events is associated with improved survival in cancer patients treated with checkpoint inhibition.

N. LeBoeuf, K. Reynolds, L. Thompson, 2022, Journal of the American Academy of Dermatology.

Evaluating patterns of co-occurrence between cutaneous and non-cutaneous immune-related adverse events after immune checkpoint inhibitor therapy.

K. Reynolds, L. Thompson, S.T. Chen, 2022, Journal of American Academy of Dermatology.

Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anti-cancer therapies: a multicenter retrospective study.

N. LeBoeuf, K. Reynolds, L. Thompson, 2022, Journal of the American Academy of Dermatology.

Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors.

K. Reynolds, L. Thompson, S.T. Chen, 2022, European journal of cancer.